What is ARQT's current stock price?

ARQT (Arcutis Biotherapeutics, Inc.) is currently trading at $20.86 with a market cap of $2.61B.

What sector is Arcutis Biotherapeutics, Inc. in?

Arcutis Biotherapeutics, Inc. (ARQT) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is ARQT a good stock to buy?

Analysts have a Buy consensus on ARQT with a price target of $35.50. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

ARQT Arcutis Biotherapeutics, Inc.

Healthcare

$20.86-0.71%ClosedMarket Cap: $2.61B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

14.23

P/S

6.28

EV/EBITDA

202.59

DCF Value

$-164.74

FCF Yield

1.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

90.9%

Operating Margin

0.8%

Net Margin

-0.6%

ROE

-1.4%

ROA

-0.5%

ROIC

1.1%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$105.4M	$-11.3M	$—
Q4 null	$129.5M	$17.4M	$—
FY null	$376.1M	$-16.1M	$—
Q3 null	$99.2M	$7.4M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$35.50

Target (Median)

$35.50

Target Range

$34.00 - $37.00

2 Strong Buy5 Buy1 Hold0 Sell0 Strong Sell

NeedhamBuy

2026-05-07

MizuhoOutperform

2026-03-02

GuggenheimBuy

2026-02-27

NeedhamBuy

2026-02-26

TD CowenBuy

2026-02-26

Trading Activity

Insider Trades

View All

Vairavan Lathaofficer: SVP Chief Financial Officer

SellWed May 13

Burnett Patrickofficer: See Remarks

SellWed May 13

Watanabe Todddirector, officer: See Remarks

SellWed May 06

Vairavan Lathaofficer: SVP Chief Financial Officer

SellWed May 06

Matsuda Masaruofficer: See Remarks

SellWed May 06

Congress Trades

View All

Gilbert CisnerosBuy

Wed Apr 08

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.59

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Peers